262 related articles for article (PubMed ID: 27095757)
21. Clinical relevance of HCV antiviral drug resistance.
Welsch C; Zeuzem S
Curr Opin Virol; 2012 Oct; 2(5):651-5. PubMed ID: 23006585
[TBL] [Abstract][Full Text] [Related]
22. Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries.
Echeverría N; Betancour G; Gámbaro F; Hernández N; López P; Chiodi D; Sánchez A; Boschi S; Fajardo A; Sóñora M; Moratorio G; Cristina J; Moreno P
Virus Res; 2016 Sep; 223():140-6. PubMed ID: 27449600
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis C Virus: Viral Quasispecies and Genotypes.
Tsukiyama-Kohara K; Kohara M
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29271914
[TBL] [Abstract][Full Text] [Related]
24. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Asselah T; Marcellin P
Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
[TBL] [Abstract][Full Text] [Related]
25. HCV drug resistance and DAA agents.
Szymanek A; Krzysztof S
Przegl Epidemiol; 2013; 67(3):403-6, 513-5. PubMed ID: 24340550
[TBL] [Abstract][Full Text] [Related]
26. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
Butt AA; Kanwal F
Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
[TBL] [Abstract][Full Text] [Related]
27. Vedroprevir in the management of hepatitis C virus infection.
Abutaleb A; Kottilil S
Expert Opin Investig Drugs; 2017 Dec; 26(12):1399-1402. PubMed ID: 29053394
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis C treatment: an incipient therapeutic revolution.
deLemos AS; Chung RT
Trends Mol Med; 2014 Jun; 20(6):315-21. PubMed ID: 24636306
[TBL] [Abstract][Full Text] [Related]
29. Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.
Martin MT; Deming P
Pharmacotherapy; 2017 Jun; 37(6):735-747. PubMed ID: 28374965
[TBL] [Abstract][Full Text] [Related]
30. Current race in the development of DAAs (direct-acting antivirals) against HCV.
De Clercq E
Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists.
Deming P; Martin MT; Chan J; Dilworth TJ; El-Lababidi R; Love BL; Mohammad RA; Nguyen A; Spooner LM; Wortman SB
Pharmacotherapy; 2016 Feb; 36(2):203-17. PubMed ID: 26846728
[TBL] [Abstract][Full Text] [Related]
32. [Research progress of hepatitis C in 2018].
Wei L
Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):6-9. PubMed ID: 30685916
[TBL] [Abstract][Full Text] [Related]
33. Entry inhibitors: New advances in HCV treatment.
Qian XJ; Zhu YZ; Zhao P; Qi ZT
Emerg Microbes Infect; 2016 Jan; 5(1):e3. PubMed ID: 26733381
[TBL] [Abstract][Full Text] [Related]
34. Development and Validation of a Template-Independent Next-Generation Sequencing Assay for Detecting Low-Level Resistance-Associated Variants of Hepatitis C Virus.
Wei B; Kang J; Kibukawa M; Chen L; Qiu P; Lahser F; Marton M; Levitan D
J Mol Diagn; 2016 Sep; 18(5):643-656. PubMed ID: 27393904
[TBL] [Abstract][Full Text] [Related]
35. INCREASE OF LIPIDS DURING HCV TREATMENT: VIRUS ACTION OR MEDICATION?
Andrade VG; Yamashiro FDS; Oliveira CV; Kurozawa LL; Moreira A; Silva GF
Arq Gastroenterol; 2018; 55(2):184-187. PubMed ID: 30043871
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis C Virus and Antiviral Drug Resistance.
Kim S; Han KH; Ahn SH
Gut Liver; 2016 Nov; 10(6):890-895. PubMed ID: 27784846
[TBL] [Abstract][Full Text] [Related]
37. [Update on hepatitis C therapy. New drugs, treatment response monitoring and emergence of resistance].
Chueca Porcuna N; Alvarez Estévez M; Parra Ruiz J; Hernández Quero J; García García F
Enferm Infecc Microbiol Clin; 2013 Feb; 31 Suppl 1():40-7. PubMed ID: 23453230
[TBL] [Abstract][Full Text] [Related]
38. Current Treatment Options in Patients with Hepatitis C Virus Genotype 6.
Nguyen NH; Nguyen MH
Gastroenterol Clin North Am; 2015 Dec; 44(4):871-81. PubMed ID: 26600225
[TBL] [Abstract][Full Text] [Related]
39. The role of HCV proteins on treatment outcomes.
Kumthip K; Maneekarn N
Virol J; 2015 Dec; 12():217. PubMed ID: 26666318
[TBL] [Abstract][Full Text] [Related]
40. Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time.
Cuypers L; Ceccherini-Silberstein F; Van Laethem K; Li G; Vandamme AM; Rockstroh JK
Rev Med Virol; 2016 Nov; 26(6):408-434. PubMed ID: 27401933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
